Anthrax toxin-mediated delivery of the Pseudomonas exotoxin a enzymatic domain to the cytosol of tumor cells via cleavable ubiquitin fusions

mBio

Volumn 4, Issue 3, 2013, Pages

  Bachran, Christopher ^a   Morley, Thomas ^a   Abdelazim, Suzanne ^a   Fattah, Rasem J ^a   Liu, Shihui ^a   Leppla, Stephen H ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRAX TOXIN; ARGININE; DEUBIQUITINATING ENZYMES; HYBRID PROTEIN; LYSINE; PSEUDOMONAS EXOTOXIN; PSEUDOMONAS EXOTOXIN A; UBIQUITIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BACTERIAL ANTIGEN; BACTERIAL TOXIN; BIOLOGICAL PRODUCT; CARRIER PROTEIN; EXOTOXIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; TOXA PROTEIN, PSEUDOMONAS AERUGINOSA; VIRULENCE FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; CYTOSOL; CYTOTOXICITY; DRUG DELIVERY SYSTEM; ENZYME ACTIVE SITE; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; MALE; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN DOMAIN; SEQUENCE ANALYSIS; TOXIN ANALYSIS; TUMOR CELL; UBIQUITINATION; ANIMAL; C57BL MOUSE; DISEASE MODEL; GENETICS; METABOLISM; NEOPLASMS; TREATMENT OUTCOME; TUMOR CELL LINE;

BACILLUS ANTHRACIS; BACTERIA (MICROORGANISMS); MAMMALIA; MUS; PSEUDOMONAS EXOTOXIN;

ADP RIBOSE TRANSFERASES; ANIMALS; ANTIGENS, BACTERIAL; ANTINEOPLASTIC AGENTS; BACTERIAL TOXINS; BIOLOGICAL PRODUCTS; CARRIER PROTEINS; CELL LINE, TUMOR; CYTOSOL; DISEASE MODELS, ANIMAL; EXOTOXINS; FEMALE; MICE; MICE, INBRED C57BL; NEOPLASMS; PROTEOLYSIS; RECOMBINANT FUSION PROTEINS; TREATMENT OUTCOME; UBIQUITIN; VIRULENCE FACTORS;

EID: 84879581437     PISSN: 21612129     EISSN: 21507511     Source Type: Journal    
DOI: 10.1128/mBio.00201-13     Document Type: Article

References (45)

1. Alfano RW, Leppla SH, Liu S, Bugge TH, Duesbery NS, Frankel AE. 2008. Potent inhibition of tumor angiogenesis by the matrix metalloproteinase-activated anthrax lethal toxin: implications for broad anti-tumor efficacy. Cell Cycle 7:745-749.
2. Hetzel C, Bachran C, Tur MK, Fuchs H, Stöcker M. 2009. Improved immunotoxins with novel functional elements. Curr. Pharm. Des. 15: 2700-2711.
3. Weldon JE, Pastan I. 2011. A guide to taming a toxin-recombinant immunotoxins constructed from Pseudomonas exotoxin A for the treatment of cancer. FEBS J. 278:4683-4700.
4. Bachran C, Dürkop H, Sutherland M, Bachran D, Müller C, Weng A, Melzig MF, Fuchs H. 2009. Inhibition of tumor growth by targeted toxins in mice is dramatically improved by saponinum album in a synergistic way. J. Immunother. 32:713-725.
5. Liu S, Netzel-Arnett S, Birkedal-Hansen H, Leppla SH. 2000. Tumor cell-selective cytotoxicity of matrix metalloproteinase-activated anthrax toxin. Cancer Res. 60:6061-6067.
6. Liu S, Redeye V, Kuremsky JG, Kuhnen M, Molinolo A, Bugge TH, Leppla SH. 2005. Intermolecular complementation achieves high specificity tumor targeting by anthrax toxin. Nat. Biotechnol. 23:725-730.
7. Liu S, Wang H, Currie BM, Molinolo A, Leung HJ, Moayeri M, Basile JR, Alfano RW, Gutkind JS, Frankel AE, Bugge TH, Leppla SH. 2008. Matrix metalloproteinase-activated anthrax lethal toxin demonstrates high potency in targeting tumor vasculature. J. Biol. Chem. 283:529-540.
8. Abi-Habib RJ, Singh R, Liu S, Bugge TH, Leppla SH, Frankel AE. 2006. A urokinase-activated recombinant anthrax toxin is selectively cytotoxic to many human tumor cell types. Mol. Cancer Ther. 5:2556-2562.
9. London E, Luongo CL. 1989. Domain-specific bias in arginine/lysine usage by protein toxins. Biochem. Biophys. Res. Commun. 160:333-339.
10. Falnes PO, Olsnes S. 1998. Modulation of the intracellular stability and toxicity of diphtheria toxin through degradation by the N-end rule pathway. EMBO J. 17:615-625.
11. Varshavsky A. 2011. The N-end rule pathway and regulation by proteolysis. Protein Sci. 20:1298-1345.
12. Gupta PK, Moayeri M, Crown D, Fattah RJ, Leppla SH. 2008. Role of N-terminal amino acids in the potency of anthrax lethal factor. PLoS One 3:e3130. e-http://dx.doi.org/10.1371/journal.pone.0003130. Cleavable Ubiquitin Fusion Toxins
13. Wesche J, Elliott JL, Falnes PO, Olsnes S, Collier RJ. 1998. Characterization of membrane translocation by anthrax protective antigen. Biochemistry 37:15737-15746.
14. Thrower JS, Hoffman L, Rechsteiner M, Pickart CM. 2000. Recognition of the polyubiquitin proteolytic signal. EMBO J. 19:94-102.
15. Kim HT, Kim KP, Lledias F, Kisselev AF, Scaglione KM, Skowyra D, Gygi SP, Goldberg AL. 2007. Certain pairs of ubiquitin-conjugating enzymes (E2s) and ubiquitin-protein ligases (E3s) synthesize nondegrad able forked ubiquitin chains containing all possible isopeptide linkages. J. Biol. Chem. 282:17375-17386.
16. Jacobson AD, Zhang NY, Xu P, Han KJ, Noone S, Peng J, Liu CW. 2009. The lysine 48 and lysine 63 ubiquitin conjugates are processed differently by the 26 S proteasome. J. Biol. Chem. 284:35485-35494.
17. Varshavsky A. 2005. Ubiquitin fusion technique and related methods. Methods Enzymol. 399:777-799.
18. Leppla SH, Martin OC, Muehl LA. 1978. The exotoxin of P. aeruginosa: a proenzyme having an unusual mode of activation. Biochem. Biophys. Res. Commun. 81:532-538.
19. Bär C, Zabel R, Liu S, Stark MJ, Schaffrath R. 2008. A versatile partner of eukaryotic protein complexes that is involved in multiple biological processes: Kti11/Dph3. Mol. Microbiol. 69:1221-1233.
20. Cronican JJ, Thompson DB, Beier KT, McNaughton BR, Cepko CL, Liu DR. 2010. Potent delivery of functional proteins into mammalian cells in vitro and in vivo using a supercharged protein. ACS Chem. Biol. 5:747-752.
21. Singh Y, Klimpel KR, Arora N, Sharma M, Leppla SH. 1994. The chymotrypsin-sensitive site, FFD315, in anthrax toxin protective antigen is required for translocation of lethal factor. J. Biol. Chem. 269: 29039-29046.
22. Yang Y, Kitagaki J, Dai RM, Tsai YC, Lorick KL, Ludwig RL, Pierre SA, Jensen JP, Davydov IV, Oberoi P, Li CC, Kenten JH, Beutler JA, Vousden KH, Weissman AM. 2007. Inhibitors of ubiquitin-activating enzyme (E1), a new class of potential cancer therapeutics. Cancer Res. 67:9472-9481.
23. Soler-Rodriguez AM, Uhr JW, Richardson J, Vitetta ES. 1992. The toxicity of chemically deglycosylated ricin A-chain in mice. Int. J. Immunopharmacol. 14:281-291.
24. Arora N, Leppla SH. 1993. Residues 1-254 of anthrax toxin lethal factor are sufficient to cause cellular uptake of fused polypeptides. J. Biol. Chem. 268:3334-3341.
25. Arora N, Leppla SH. 1994. Fusions of anthrax toxin lethal factor with Shiga toxin and diphtheria toxin enzymatic domains are toxic to mammalian cells. Infect. Immun. 62:4955-4961.
26. Liu XH, Collier RJ, Youle RJ. 2001. Inhibition of axotomy-induced neuronal apoptosis by extracellular delivery of a Bcl-XL fusion protein. J. Biol. Chem. 276:46326-46332.
27. Hobson JP, Liu S, Rønø B, Leppla SH, Bugge TH. 2006. Imaging specific cell-surface proteolytic activity in single living cells. Nat. Methods 3:259-261.
28. Hu H, Leppla SH. 2009. Anthrax toxin uptake by primary immune cells as determined with a lethal factor-beta-lactamase fusion protein. PLoS One 4:e7946. http://dx.doi.org/10.1371/journal.pone.0007946.
29. Thoren KL, Krantz BA. 2011. The unfolding story of anthrax toxin translocation. Mol. Microbiol. 80:588-595.
30. Tamayo AG, Slater L, Taylor-Parker J, Bharti A, Harrison R, Hung DT, Murphy JR. 2011. GRP78(BiP) facilitates the cytosolic delivery of anthrax lethal factor (LF) in vivo and functions as an unfoldase in vitro. Mol. Microbiol. 81:1390-1401.
31. Ralat LA, Kalas V, Zheng Z, Goldman RD, Sosnick TR, Tang WJ. 2011. Ubiquitin is a novel substrate for human insulin-degrading enzyme. J. Mol. Biol. 406:454-466.
32. Reyes-Turcu FE, Ventii KH, Wilkinson KD. 2009. Regulation and cellular roles of ubiquitin-specific deubiquitinating enzymes. Annu. Rev. Biochem. 78:363-397.
33. Stack JH, Whitney M, Rodems SM, Pollok BA. 2000. A ubiquitin-based tagging system for controlled modulation of protein stability. Nat. Biotechnol. 18:1298-1302.
34. Falnes PO, Ariansen S, Sandvig K, Olsnes S. 2000. Requirement for prolonged action in the cytosol for optimal protein synthesis inhibition by diphtheria toxin. J. Biol. Chem. 275:4363-4368.
35. Lim KL, Chew KC, Tan JM, Wang C, Chung KK, Zhang Y, Tanaka Y, Smith W, Engelender S, Ross CA, Dawson VL, Dawson TM. 2005. Parkin mediates nonclassical, proteasomal-independent ubiquitination of synphilin-1: implications for Lewy body formation. J. Neurosci. 25: 2002-2009.
36. Heisler I, Keller J, Tauber R, Sutherland M, Fuchs H. 2003. A cleavable adapter to reduce nonspecific cytotoxicity of recombinant immunotoxins. Int. J. Cancer 103:277-282.
37. Goyal A, Batra JK. 2000. Inclusion of a furin-sensitive spacer enhances the cytotoxicity of ribotoxin restrictocin containing recombinant single chain immunotoxins. Biochem. J. 345:247-254.
38. Wang F, Ren J, Qiu XC, Wang LF, Zhu Q, Zhang YQ, Huan Y, Meng YL, Yao LB, Chen SY, Xu YM, Yang AG. 2010. Selective cytotoxicity to HER2-positive tumor cells by a recombinant e23sFv-TD-tBID protein containing a furin cleavage sequence. Clin. Cancer Res. 16:2284-2294.
39. Deichsel H, Friedel S, Detterbeck A, Coyne C, Hamker U, MacWilliams HK. 1999. Green fluorescent proteins with short half-lives as reporters in Dictyostelium discoideum. Dev. Genes Evol. 209:63-68.
40. Tcherniuk SO, Chroboczek J, Balakirev MY. 2005. Construction of tumor-specific toxins using ubiquitin fusion technique. Mol. Ther. 11: 196-204.
41. Liu S, Leung HJ, Leppla SH. 2007. Characterization of the interaction between anthrax toxin and its cellular receptors. Cell. Microbiol. 9:977-987.
42. Bachran C, Sutherland M, Bachran D, Fuchs H. 2007. Quantification of diphtheria toxin mediated ADP-ribosylation in a solid-phase assay. Clin. Chem. 53:1676-1683.
43. Yeudall WA, Crawford RY, Ensley JF, Robbins KC. 1994. MTS1/CDK4I is altered in cell lines derived from primary and metastatic oral squamous cell carcinoma. Carcinogenesis 15:2683-2686.
44. Liu S, Leppla SH. 2003. Cell surface tumor endothelium marker 8 cytoplasmic tail-independent anthrax toxin binding, proteolytic processing, oligomer formation, and internalization. J. Biol. Chem. 278:5227-5234.
45. Newman ZL, Leppla SH, Moayeri M. 2009. CA-074Me protection against anthrax lethal toxin. Infect. Immun. 77:4327-4336.